PA Marks

Molecular Biology · 2000–2009

A researcher in the Science corpus: 13 papers; trusts 15 researchers and is trusted by 18 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 100 citations into it; #2,747 of 17,773 by trust here, #3,102 by citations
• Oncology — 22 citations into it
• Cellular and Molecular Neuroscience — 7 citations into it; #2,532 of 2,998 by trust here, #1,484 by citations
• Epidemiology — 5 citations into it
• Immunology — 5 citations into it

Whom PA Marks trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. C. Monneret
2. Weisheng Xu
3. V. Richon
4. S. Minucci
5. Jessica E. Bolden
6. Elias S. J. Arnér
7. Pier Giuseppe Pelicci
8. R. Parmigiani
9. M. Peart
10. Xuejun Jiang

Who trusts PA Marks overall

1. S. Baylin
2. M. Haberland
3. Madhusoodanan Mottamal
4. Weisheng Xu
5. Ricky W. Johnstone
6. S. Minucci
7. Xiang-Jiao Yang
8. W-S Xu
9. Rusty L. Montgomery
10. Peter A. Jones

Papers from PA Marks's perspective

Ordered by how strongly the researchers PA Marks trusts endorse each paper. Same corpus, a different order for every researcher.

1. Histone deacetylases and cancer: causes and therapies (Nature Reviews. Cancer)
2. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. (Cell)
3. The language of covalent histone modifications (Nature)
4. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. (Journal of Molecular Biology)
5. The silencing protein SIR2 and its homologs are NAD-dependent protein deacetylases. (Proceedings of the National Academy of Sciences of the United States of America)
6. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. (Molecules and Cells)
7. Anticancer activities of histone deacetylase inhibitors (Nature reviews. Drug discovery)
8. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-mediated apoptosis. (Molecules and Cells)
9. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. (Structure)
10. The Sir2 family of protein deacetylases. (Annual Review of Biochemistry)

Their papers

• Histone deacetylases and cancer: causes and therapies (2001) — 1,931 citations
• Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. (2000) — 1,174 citations
• Apoptotic and autophagic cell death induced by histone deacetylase inhibitors (2004) — 605 citations
• Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug (2007) — 1,191 citations
• Histone deacetylase inhibitors: molecular mechanisms of action (2007) — 1,515 citations
• Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. (2000) — 1,225 citations
• Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. (2004) — 600 citations
• Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease (2003) — 860 citations
• Histone Deacetylase Inhibitors: Potential in Cancer Therapy (2009) — 728 citations
• Discovery and development of SAHA as an anticancer agent (2007) — 602 citations
• Histone Deacetylase Inhibitors: Overview and Perspectives (2007) — 1,159 citations
• Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. (2003) — 659 citations
• Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. (2000) — 618 citations